PD Dr. Markus Hecht

Medizinische Fakultät Department of Radiation Oncology

Therapies for synchronous malignomas - the importance of interdisciplinary oncology (2021) Müller SK, Haderlein M, Traxdorf M, Semrau S, Agaimy A, Lettmaier S, Gostian AO, et al. Journal article, Editorial Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological Response (2021) Olmos M, Glajzer J, Büntemeyer TO, Frohwitter G, Ries J, Eckstein M, Hecht M, et al. Journal article Longitudinal C-reactive protein (CRP) as an individualized dynamic predictor for metastatic cancer patients treated with immune checkpoint inhibitors: Findings from the prospective ST-ICI cohort. (2021) Zhou JG, Ma H, Gaipl U, Frey B, Hecht M, Fietkau R Conference contribution A Prospective Real-World Multi-Center Study to Evaluate Progression-Free and Overall Survival of Radiotherapy with Cetuximab and Platinum-Based Chemotherapy with Cetuximab in Locally Recurrent Head and Neck Cancer (2021) Hecht M, Hahn D, Wolber P, Hautmann MG, Reichert D, Weniger S, Belka C, et al. Journal article Precautionary documents in patients with head and neck cancer - status quo and factors influencing their creation (2021) Allner M, Gostian M, Balk M, Rupp R, Hecht M, Ostgathe C, Müller SK, et al. Conference contribution Time dependency of adjuvant therapy in advanced head-and-necksquamous-cell-carcinoma of unknown primary (CUP)-patients (2021) Balk M, Rupp R, Grundtner P, Müller SK, Allner M, Traxdorf M, Eckstein M, et al. Conference contribution Re-Irradiation for Patients with Head and Neck Squamous Cell Carcinoma - A multicenter Analysis of 253 Patients of the jDEGRO Trial Group (2021) Roesch J, Oertel M, Dobiasch S, Fabian A, Fleischmann D, Von Der Gruen J, Hering D, et al. Conference contribution Primary Results of the phase II CheckRad-CD8 Trial: First-Line Treatment of locally advanced Head and Neck Tumors with double Checkpoint Blockade and Radiotherapy dependent on intratumoral CD8+T-Cell Infiltration (2021) Hecht M, Eckstein M, Rutzner S, Von Der Gruen J, Illmer T, Klautke G, Laban S, et al. Conference contribution Experience gained with Durvalumab Maintenance Therapy after definitive Chemoradiotherapy in Patients with NSCLC: Survival- and Toxicity Data from Routine clinical Practice (2021) Lettmaier S, Hecht M, Weissmann T, Fietkau R Conference contribution Low-dose Radiotherapy is highly effective in the Treatment of Patients with painful Ankle Arthrosis (2021) Weissmann T, Putz F, Hecht M, Zhou J, Donaubauer AJ, Fietkau R, Gaipl U, et al. Conference contribution